ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

US Judge Upholds Validity Of Merck's Vytorin Patent

By Peter Loftus Of DOW JONES NEWSWIRES A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (MRK) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years. In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable. Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017. Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable. Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday. On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said. A Mylan spokeswoman couldn't immediately be reached. Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million. Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581;

Stock News for Merck (MRK)
12/01/201607:00:00FDA Grants Priority Review to Supplemental Biologics License...
11/30/201607:00:00New KEYTRUDA® (pembrolizumab) Data to be Presented at 17th World...
11/29/201607:00:00Actress Bellamy Young, Merck, and Leading Lung Cancer Advocates...
11/28/201607:00:00FDA Grants Priority Review to Merck’s Supplemental Biologics L...
11/28/201600:40:00Amazon Broadens Cloud Services as Big Companies Sign On
11/28/201600:30:00Amazon Broadens Cloud Services as Big Companies Sign On
11/24/201609:29:00House GOP Business-Tax Plan Upends U.S. Policy, Bares Corporate...
11/23/201610:02:00Eli Lilly Alzheimer's Drug Fails Late-Stage Trial -- 3rd Update
11/23/201609:44:00Eli Lilly's Late Stage Alzheimer's Trial Fails To Achieve Goal...
11/22/201613:22:00Merck Announces Increased Quarterly Dividend
11/22/201607:00:00New KEYTRUDA® (pembrolizumab) Data in Blood Cancers to be Presented...
11/18/201613:51:00Sanofi to Stop Production of Bladder-Cancer Drug BCG -- Update
11/18/201611:23:00Sanofi to Stop Production of Bladder-Cancer Drug BCG
11/17/201609:00:00Merck Foundation Announces $10 Million Initiative to Improve...
11/15/201603:30:00Merck Raises Guidance
11/13/201608:00:00Merck Announces Findings for Investigational Triple-Combination...
11/12/201611:45:00Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Su...
11/12/201608:00:00Merck Announces Presentation of New Findings for ZEPATIER™...
11/10/201617:30:44Statement of Changes in Beneficial Ownership (4)
11/08/201611:52:13Statement of Changes in Beneficial Ownership (4)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations